Now I have enough anchors. Let me compile the final review.

**Calibration analysis:**

Anchors retrieved across all rounds:
- BioDiscoveryAgent (6.40, Accept): Similar LLM-agent-for-biology theme but evaluates on 6 datasets with quantitative metrics. Stronger validation.
- PerturbQA/SUMMER (4.60, Accept): Novel benchmark + method for LLM reasoning on perturbation data. Weak baselines but interesting idea.
- LLM4GRN (4.33, Reject): LLM for gene regulatory networks, limited validation, inconsistent performance across datasets.
- GenoAgent (4.00, Reject): LLM agents for gene expression, limited result clarity, no source code.
- scMPT (3.40, Reject): LLM to complement single-cell models, unclear contribution.
- DrugAgent (2.50, Reject): Multi-agent LLM for drug-target interaction, poor baselines.
- CellPLM (6.50, Accept): Pre-trained cell language model, thorough evaluation.
- Small Molecule Optimization (5.75, Reject): LLM for drug design, good method but limited evaluation.

**Round 1 bracket: 4.0–5.0.** The paper has a genuinely novel and well-formalized idea (ICS/ICD/RS), thorough Stage 1 ablation, and dual-level demonstration — these place it above LLM4GRN (4.33) and GenoAgent (4.00). However, it has circular reasoning in the enrichment validation, no ground-truth evaluation, single dataset, and significant overclaiming — these place it below PerturbQA (4.60, Accept) and well below BioDiscoveryAgent (6.40). The paper is similar to PerturbQA in having an interesting idea with insufficient validation, but the circular reasoning issue is a distinct additional concern.

Final score: **4.5**

---

## Summary
The paper proposes HYPOGENEAGENT, an LLM-agent framework that uses functional annotation consistency as a biology-aware signal to select clustering resolution in single-cell/Perturb-seq analysis. An LLM generates ranked GO hypotheses for each cluster; cosine similarities between these hypotheses are combined into an Intra-Cluster Similarity (ICS) and Inter-Cluster Distinctiveness (ICD) score, forming a Resolution Score optimized across Leiden resolutions. The method is demonstrated on a K562 CRISPRi Perturb-seq dataset.

## Strengths
- **Novel closed-loop framework filling a real gap**: Prior LLM-based annotation tools (GeneAgent, BioDiscoveryAgent, PerTurboAgent) act post-hoc on fixed clusters; none feeds functional feedback into clustering hyperparameters. HYPOGENEAGENT's use of annotation consistency as a resolution-selection signal is a genuinely creative contribution, clearly motivated in Section 2 (line 37) and formalized in Section 3.4.
- **Clean, interpretable mathematical formalization**: The ICS, ICD, and RS definitions are well-motivated and precisely stated. ICS_k = (1/4) Σ sim(h_{k1}, h_{kh}) measures within-cluster annotation agreement; ICD_k = (1/(C-1)) Σ sim(h_{k1}, h_{l1}) measures between-cluster overlap; RS_k = w·ICS_k + (1-w)·(1-ICD_k) combines them into a principled single-objective score.
- **Thorough Stage 1 configuration benchmarking**: The paper systematically ablates 5 LLM backbones, 3 embedding methods, 2 prompt variants, and temperature sweeps on curated GOBP gene sets before deployment. This establishes that thinking LLMs with hypothesis prompts perform best and that GPT-o3's self-reported confidence correlates with actual accuracy (Figure S3a), validating the ranked-hypothesis design.
- **Dual-level application (GEX and perturbation)**: Demonstrating the framework at both gene-expression level (marker gene signatures) and perturbation level (CRISPR-targeted gene labels) shows flexibility across two distinct biological input types.

## Weaknesses

### Fatal
None.

### Major
- **Circular reasoning undermines the closest thing to independent validation (Section 4.4.3)**: The functional enrichment-based Resolution Score peaks at r=0.7 (Figure 6a), yet the authors write: "consider the reasonability of cluster numbers we expected, so the selected resolution can be 0.5 or 0.4." This explicitly uses a prior belief about the correct answer to overrule the metric's own optimum. The paper then claims this "validates that the clusters produced at the Resolution Score maximum are biologically coherent and align with the expected results from HYPOGENEAGENT." But the enrichment analysis's own optimum disagrees with HYPOGENEAGENT's selection — this is not a validation, it is a disagreement that the authors resolve by fiat. The paper needs to either explain why r=0.7 is suboptimal for enrichment, or honestly acknowledge the discrepancy.

- **No ground-truth evaluation of resolution quality**: The paper's central claim is that the Resolution Score selects "biologically meaningful" resolutions that "recover known perturbation effects better than classical metrics" (Abstract). But there is no quantitative evaluation against any external criterion. The K562 Perturb-seq dataset has known CRISPR guide-to-gene mappings that could serve as partial ground truth — e.g., Adjusted Rand Index between clustering labels and known pathway groupings, or measuring whether perturbations targeting the same pathway co-cluster. Instead, validation rests on UMAP aesthetics ("well-separated clusters") and the circular enrichment comparison. This is the single most important gap: the core claim is unsupported by quantitative evidence.

- **Single-dataset evaluation insufficient for claimed generality**: The entire Stage 2 evaluation uses one dataset (K562 CRISPRi Perturb-seq, Replogle et al. 2022). Yet the conclusion claims HYPOGENEAGENT is "a powerful, general-purpose tool for single-cell, perturb-seq and multi-omics analyses" establishing "a general methodology." One dataset cannot support these claims. Different cell types, organisms, and perturbation modalities could substantially change LLM annotation behavior and resolution score dynamics.

### Minor
- **No robustness analysis across LLM runs**: LLM outputs are stochastic. The paper uses a single LLM call per cluster per resolution. Stage 1 shows temperature has minimal effect on GPT-4o, but Stage 2 uses GPT-o3 which was not tested for output stability. Without reporting RS_k variance and selected-resolution stability across multiple independent LLM calls, it is impossible to know whether the method reliably converges on the same answer.

- **Potential information leakage in w=1/3 selection**: The paper states w=1/3 "was chosen by a small grid search and found to give a stable ordering of resolutions across data sets" (line 79). If this grid search was performed on the K562 dataset used for evaluation, the selected w leaks information. The paper should specify which datasets were used.

- **Stage 1 validates annotation accuracy, not resolution selection**: The comprehensive Stage 1 ablation (median cosine similarity ~0.4–0.5 against ground truth GOBP sets) establishes that the LLM can generate decent GO annotations. However, this validates the annotation sub-task, not the distinct claim that annotation consistency is a reliable signal for resolution selection. The paper conflates these two propositions.

- **No cost/runtime analysis**: The claim that the pipeline runs "in minutes, orders of magnitude faster than manual curation" (line 261) lacks runtime breakdown or API cost estimation. The method requires many LLM API calls (5 hypotheses × many clusters × 10 resolutions), which matters for practical adoption.

## Nice-to-Haves
- Validate the core assumption empirically: show that high ICS correlates with enrichment of known pathways and that low ICD corresponds to genuinely distinct biology.
- Sensitivity analysis on gene signature size (number of top marker genes used as input).
- Comparison with MultiK or other dedicated cluster-number selection tools.
- Discussion of how many LLM API calls the full pipeline requires.

## Removed Points
- Harsh critic's "LLM annotation consistency ≠ biological correctness" concern is partially valid but is captured more precisely in the major weakness about missing ground-truth evaluation and the minor weakness about Stage 1 only validating annotation accuracy.
- Strengths about the paper "addressing an important problem" or "filling a gap" are generic and removed in favor of concrete, evidence-backed strengths.
- Formatting/style concerns from parser artifacts are not paper problems.

## Novel Insights
The genuinely novel observation is that LLM annotation consistency (within-cluster agreement + between-cluster distinctiveness) can serve as a biology-aware objective function for clustering hyperparameter selection — a signal that traditional statistics like silhouette and modularity miss. The two-stage experimental protocol (configuration selection → fixed deployment) is also a sound methodological contribution for LLM-agent evaluation in genomics. However, the gap between validating annotation accuracy (Stage 1) and validating resolution selection (Stage 2) remains bridged more by assumption than by evidence.

## Suggestions
1. Define and measure against ground truth using the known CRISPR guide-to-gene mappings (e.g., ARI between clustering labels and known pathway groupings).
2. Repeat the full resolution sweep 3–5 times with independent LLM calls and report RS_k variance and selected-resolution stability.
3. Test on at least one additional dataset to support the generality claim.
4. Reconcile the enrichment analysis discrepancy: either explain why r=0.7 is suboptimal for enrichment, or honestly report that the enrichment analysis selects a different resolution and discuss why.
5. Specify which datasets were used for the w=1/3 grid search to address the information leakage concern.

## Score and Decision

**Round 1 bracket: 4.0–5.0.** The paper's novel idea and clean formalization place it above rejected LLM-for-biology papers like LLM4GRN (4.33) and GenoAgent (4.00). However, the circular reasoning in enrichment validation, missing ground-truth evaluation, and single-dataset evaluation with overclaiming place it below PerturbQA (4.60, Accept) and well below BioDiscoveryAgent (6.40, Accept with 6 datasets and quantitative metrics). The paper has a good core idea with inadequate validation — a common profile for borderline reject at ICLR.

**All anchors retrieved:**
| Anchor | Score | Decision | Round | Comparison |
|--------|-------|----------|-------|------------|
| BioDiscoveryAgent | 6.40 | Accept | 1 | Similar LLM-agent-for-biology theme but 6 datasets, quantitative metrics, stronger validation |
| PerturbQA/SUMMER | 4.60 | Accept | 1 | Novel benchmark + method, weak baselines but interesting idea; our paper has similar gap in validation |
| LLM4GRN | 4.33 | Reject | 1 | LLM for GRN discovery, limited validation; our paper has cleaner math but similar evaluation weakness |
| GenoAgent | 4.00 | Reject | 1 | LLM agents for gene expression, unclear results; our paper is more clearly presented |
| scMPT | 3.40 | Reject | 1 | LLM complementing single-cell models, unclear contribution |
| DrugAgent | 2.50 | Reject | 1 | Multi-agent LLM for drug-target, poor baselines |
| CellPLM | 6.50 | Accept | 1 | Thorough evaluation; stronger than our paper |
| Small Molecule Optimization | 5.75 | Reject | 1 | Good method, limited evaluation |
| ZerOmics | 4.67 | Reject | 1 | Zero-shot LLM for SC tasks; comparable idea quality but better evaluation |
| PerturbQA | 4.60 | Accept | 1 | Most similar anchor; our paper has weaker validation |

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>